These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23899731)

  • 21. Is fluorescent cystoscopy of cost/benefit/therapeutic value for carcinoma in situ of the bladder? No (a difficult task).
    O'Brien T
    J Urol; 2013 Jul; 190(1):20-1. PubMed ID: 23602484
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bladder carcinoma].
    Lycklama à Nijeholt AA
    Ned Tijdschr Geneeskd; 1992 Jun; 136(23):1097-102. PubMed ID: 1603169
    [No Abstract]   [Full Text] [Related]  

  • 23. [FRancilian Oncogeriatric Group (FROG)'s focus on management of elderly patients with bladder cancer].
    Ghebriou D; Avenin D; Caillet P; Mongiat-Artus P; Durdux C; Massard C; Culine S
    Bull Cancer; 2014 Sep; 101(9):841-55. PubMed ID: 25296412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in urinary bladder cancer detection.
    Bhatt J; Cowan N; Protheroe A; Crew J
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):929-39. PubMed ID: 22845408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer of the urogenital tract: bladder cancer. The accuracy of clinical vs. surgical staging.
    Baker R
    JAMA; 1968 Nov; 206(8):1770-3 passim. PubMed ID: 5754828
    [No Abstract]   [Full Text] [Related]  

  • 26. Transitional cell carcinoma of the urinary bladder: a clinicopathological study.
    Matalka I; Bani-Hani K; Shotar A; Bani Hani O; Bani-Hani I
    Singapore Med J; 2008 Oct; 49(10):790-4. PubMed ID: 18946612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
    Orsola A; Cecchini L; Morote J
    Eur Urol; 2009 Jan; 55(1):e15-6; author reply e17-8. PubMed ID: 18692301
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving a nurse-led flexible cystoscopy service through audit.
    Kilburn K
    Prof Nurse; 2002 Jun; 17(10):601-4. PubMed ID: 12087708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease.
    Kakizoe T; Mucci LA; Albertsen PC; Droller MJ
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):191-212. PubMed ID: 18815934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic markers as promising prognosticators for bladder cancer.
    Kim YK; Kim WJ
    Int J Urol; 2009 Jan; 16(1):17-22. PubMed ID: 18721202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current management of invasive and metastatic transitional cell carcinoma of the bladder.
    Thrasher JB; Crawford ED
    J Urol; 1993 May; 149(5):957-72. PubMed ID: 8483247
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary on association of clinical prostate and bladder cancers.
    Nieder AM
    J Urol; 2008 May; 179(5 Suppl):S6. PubMed ID: 18405754
    [No Abstract]   [Full Text] [Related]  

  • 33. Bibliography. Current world literature. Bladder cancer.
    Curr Opin Urol; 2006 Sep; 16(5):386-9. PubMed ID: 16905987
    [No Abstract]   [Full Text] [Related]  

  • 34. Intravesical therapy: does it affect the natural history of superficial bladder cancer?
    Lamm DL; Griffith JG
    Semin Urol; 1992 Feb; 10(1):39-44. PubMed ID: 1565903
    [No Abstract]   [Full Text] [Related]  

  • 35. Intermediate-risk group in patients with transitional cell carcinoma of the bladder: prediction of high-risk patients in this heterogeneous group.
    Yencilek F; Onal B; Erozenci A; Talat Z; Ataus S
    Urol Int; 2009; 83(3):295-9. PubMed ID: 19829029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bladder cancer.
    Soloway MS
    Urology; 1996 Oct; 48(4):631. PubMed ID: 8886073
    [No Abstract]   [Full Text] [Related]  

  • 37. Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts.
    Aprikian AG; Sarkis AS; Reuter VE; Cordon-Cardo C; Sheinfeld J
    Semin Urol; 1993 Aug; 11(3):137-44. PubMed ID: 8210835
    [No Abstract]   [Full Text] [Related]  

  • 38. The management of superficial transitional cell carcinoma of the bladder.
    Sengupta S; Blute ML
    Urology; 2006 Mar; 67(3 Suppl 1):48-54; discussion 54-5. PubMed ID: 16530076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
    Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follow-up of patients with noninvasive and superficially invasive bladder cancer.
    Holmäng S
    Semin Urol Oncol; 2000 Nov; 18(4):273-9. PubMed ID: 11101090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.